Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism

• Published in: Scientific reports Vol. 11; no. 1; pp. 15056 - 13
• Main Authors: Mayer, Annalina V., Wermter, Anne-Kathrin, Stroth, Sanna, Alter, Peter, Haberhausen, Michael, Stehr, Thomas, Paulus, Frieder M., Krach, Sören, Kamp-Becker, Inge
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.07.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/378/2645/1458; 692/308/575; 692/699/476/1373; Administration, Intranasal; Adolescent; Adult; Amygdala; Autism; Autism Spectrum Disorder - diagnostic imaging; Autism Spectrum Disorder - drug therapy; Autism Spectrum Disorder - genetics; Autism Spectrum Disorder - pathology; Brain - drug effects; Brain - physiopathology; Brain mapping; Clinical trials; Double-Blind Method; Emotions; Empathy; Empathy - drug effects; Functional magnetic resonance imaging; Gene polymorphism; Genotype; Humanities and Social Sciences; Humans; Intellectual disabilities; Magnetic Resonance Imaging; Male; multidisciplinary; Oxytocin; Oxytocin - administration & dosage; Pain; Patients; Placebos; Receptors, Oxytocin - genetics; Science; Science (multidisciplinary); Single-nucleotide polymorphism; Social Behavior; Translational Research, Biomedical; Young Adult
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-94407-x

Evidence suggests that intranasal application of oxytocin facilitates empathy and modulates its underlying neural processes, which are often impaired in individuals with autism spectrum disorders (ASD). Oxytocin has therefore been considered a promising candidate for the treatment of social difficulties in ASD. However, evidence linking oxytocin treatment to social behavior and brain function in ASD is limited and heterogeneous effects might depend on variations in the oxytocin-receptor gene ( OXTR ). We examined 25 male ASD patients without intellectual disability in a double-blind, cross-over, placebo-controlled fMRI-protocol, in which a single dose of oxytocin or placebo was applied intranasally. Patients performed three experiments in the MRI examining empathy for other’s physical pain, basic emotions, and social pain. All participants were genotyped for the rs53576 single-nucleotide polymorphism of the OXTR . Oxytocin increased bilateral amygdala responsiveness during the physical pain task for both painful and neutral stimuli. Other than that, there were no effects of oxytocin treatment. OXTR genotype did not significantly interact with oxytocin treatment. Our results contribute to the growing body of empirical literature suggesting heterogenous effects of oxytocin administration in ASD. To draw clinically relevant conclusions regarding the usefulness of oxytocin treatment, however, empirical studies need to consider methods of delivery, dose, and moderating individual factors more carefully in larger samples.